Sterling Capital Management’s Stoke Therapeutics STOK Stock Holding History

Sterling Capital Management’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.32K	Sell	193 -125	-39%	-$4.01K	﹤0.01%	2488
2026 Q1	$10.4K	Buy	318 +20	+7%	+$656	﹤0.01%	2358
2025 Q4	$9.46K	Buy	298 +189	+173%	+$5.68K	﹤0.01%	2630
2025 Q3	$2.56K	Buy	109 +10	+10%	+$171	﹤0.01%	2940
2025 Q2	$1.12K	Buy	99 +62	+168%	+$589	﹤0.01%	3044
2025 Q1	$246	Hold	37	–	–	﹤0.01%	3062
2024 Q4	$408	Hold	37	–	–	﹤0.01%	3058
2024 Q3	$455	Buy	+37	New	+$524	﹤0.01%	2916

Other funds holding STOK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sterling Capital Management's STOK Position: Q2 2026 in Review

Sterling Capital Management reduced its Stoke Therapeutics (STOK) stake by 39% in Q2 2026, selling an estimated $4.01K and leaving 193 shares worth $6.32K. The position accounts for ﹤0.01% of the portfolio, ranked #2488.

Sterling Capital Management first reported a position in STOK in Q3 2024 and has held it in 8 quarters since. The position peaked at $10.4K in Q1 2026. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

Sterling Capital Management held 193 shares of Stoke Therapeutics worth $6.32K as of Q2 2026.
Sterling Capital Management sold 125 Stoke Therapeutics shares in Q2 2026, an estimated $4.01K.
Stoke Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2488 holding.
Sterling Capital Management first reported a position in Stoke Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Stoke Therapeutics position peaked at $10.4K in Q1 2026.
197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.